<DOC>
	<DOCNO>NCT00319098</DOCNO>
	<brief_summary>Today , lead contender next pandemic influenza H5N1 , strain avian virus . Prevention control depend rapid production worldwide distribution specific pandemic vaccine . Candidate 'pandemic-like ' vaccine must develop tested clinical trial determine optimal formulation best vaccination schedule . This study design test healthy adult age 18 year reactogenicity immunogenicity one two administration candidate pandemic H5N1 vaccine formulate Split Virus .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity Pandemic Influenza Vaccine Adults Aged 18 Years Above</brief_title>
	<detailed_description>This study 2 phase : The study ID 107064 correspond objective &amp; outcome measure evaluate day 0 day 51 . The study ID 107217 correspond objective &amp; outcome measure evaluate day 180 . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female age 18 year time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , 30 day prior first vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day second vaccination . Administration interpandemic influenza vaccine Day 0 Day 51of study . Those study participant belong risk group eligible receive annual interpandemic influenza vaccine ( accordance local regulation ) receive annual vaccination day 51 end study Day 180 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior first administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History chronic alcohol consumption and/or drug abuse . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Major congenital defect serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . ( Subjects suffer seasonal allergy asthma inhalative treatment include ) . Acute disease time enrolment . Administration immunoglobulins and/or blood product within 3 month precede first administration study vaccine study . Lactating woman Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first vaccination , plan use study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adjuvanted pandemic influenza candidate vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>